

3742

PATENT  
ATTORNEY DOCKET NO. 044481-5060-01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Robert M. SCARBOROUGH et al.

Group Art Unit: Unassigned

Application No.: 09/920,325

Examiner: Unassigned

Filed: August 2, 2001

For: PLATELET ADP RECEPTOR INHIBITORS

Commissioner of Patents and Trademarks  
Washington, D.C. 20231

Sir:

RECEIVED  
DEC-6 2001  
TC 3700 MAIL ROOM

N. Heven

# 4  
4/12/2003

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed, to the best of the undersigned's knowledge, before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents are enclosed. Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form.

Applicants also bring to the attention of the Examiner the following applications with a common assignee and requests consideration of the applications and any and all references therein:

Application No.

Filing Date

09/775,812

February 5, 2001

A copy of the above-listed applications is also enclosed.


This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies the documents as "prior art" against any claim in the application and Applicants determine that the cited document does not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

**EXCEPT** for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully submitted,

**MORGAN, LEWIS & BOCKIUS LLP**

  
Jeffrey A. Lindeman  
Reg. No. 34,658

Dated: December 3, 2001

**CUSTOMER NO. 009629**  
**MORGAN, LEWIS & BOCKIUS LLP**  
1800 M Street, N.W.  
Washington, D.C. 20036-5869  
(202) 467-7000

739-3000